TURKEY MEDICAL CANNABIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Turkey Medical Cannabis Market Size and Forecast – 2025 to 2032

The Turkey medical cannabis market is estimated to be valued at USD 140.7 Mn in 2025 and is expected to reach USD 430.2 Mn by 2032, exhibiting  a compound annual growth rate (CAGR) of 16.5% from 2025 to 2032. The significant growth reflects increasing investments, regulatory developments, and rising the patient awareness, positioning Turkey as a promising market in the medical cannabis sector over the forecast period.

Key Takeaways of the Turkey Medical Cannabis Market

• In 2025, the oils and extracts segment is projected to account for 53.2% share.
• The Cannabidiol (CBD) segment is expected to capture 42.1% share in 2025.
• The pain management segment is projected to hold 23.2% share in 2025.

Market Overview

A key trend driving the turkey medical cannabis market includes expanding legalization and governmental support for medical cannabis cultivation and distribution. Additionally, growing acceptance among healthcare providers and patients for cannabis-based therapies is leading to increased adoption. Technological advancements in cultivation methods and product formulations further propel market growth. Moreover, collaborations between domestic companies and international players enhance research, development, and product availability, fostering a dynamic and evolving medical cannabis landscape in Turkey.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Turkey Medical Cannabis Market, by Product Type - Oils and Extracts Segment Contribute the Highest Share of the Market Owing to their Versatility and Ease of Use

The oils and extracts segment is expected to dominate with 53.2% share in 2025, due to their adaptability in administration methods, precise dosage control, and fast-acting therapeutic effects. These forms allow patients to benefit from cannabis’ medicinal properties without the need to inhale smoke, which is often a deterrent for many medical users. The concentrated nature of oils and extracts enables manufacturers to formulate products with consistent cannabinoid profiles, which is crucial for medical applications were dosage accuracy influences treatment outcomes significantly.

Moreover, oils can be consumed sublingually or incorporated into food and beverages, making them a discreet and convenient option for patients managing chronic conditions requiring regular cannabinoid intake. Turkey’s evolving regulatory landscape favoring pharmaceutical-grade products also encourages the use of highly purified extracts over other less standardized forms like dried flowers. Additionally, the ability to tailor cannabinoid compositions (e.g., varying ratios of CBD and THC) in oil formulations offers therapeutic flexibility for treating different medical conditions under professional supervision.

Turkey Medical Cannabis Market Insights, by Derivative - Cannabidiol (CBD) Segment Holds the Highest Market Share Driven by its Broad Therapeutic Potential and Regulatory Acceptance

The Cannabidiol (CBD) segment is expected to capture 42.1% share in 2025, due to its wide range of therapeutic applications combined with a relatively favorable legal status. Unlike THC, CBD is non-psychoactive, alleviating concerns related to intoxication and dependence, and thus making it more accessible and more attractive for medical professionals and patients alike. Its versatility in addressing conditions such as anxiety, epilepsy, inflammation, and pain management has made it a cornerstone of medical cannabis therapies.

The growing global recognition of CBD’s medical benefits reinforces its adoption in Turkey, where healthcare providers are increasingly interested in evidence-based natural treatments that do not compromise patient safety. Moreover, public perception is shifting positively toward CBD, as it is perceived as a more socially acceptable cannabis derivative compared to THC-rich products. This acceptance facilitates easier product introduction and reception among patients and prescribers.

Turkey Medical Cannabis Market Insights, by Application - Pain Management Segment Leads the Market Propelled by the Urgent Need for Alternative Treatments and Chronic Condition Management

The pain management segment is projected to account for 23.2% share in 2025, due to the growing the demand for safer and more effective remedies for chronic and acute pain. Traditional therapies, especially opioids and NSAIDs, often come with significant side effects or risks of dependency, prompting both clinicians and patients to seek alternatives that offer effective relief with a reduced risk profile. Cannabis’ analgesic properties, primarily linked to its cannabinoids interacting with the endocannabinoid system, have positioned it as a promising therapeutic option in this domain.

The prevalence of chronic pain conditions such as arthritis, neuropathic pain, and cancer-related discomfort in the Turkish population underscores a substantial unmet medical need, feeding the rising interest in cannabis-based therapies. Medical cannabis products provide the advantage of multi-modal pain relief, addressing inflammation, neuropathic components, and muscle spasticity, which conventional drugs cannot always manage effectively on their own.

End User Feedback and Unmet Needs for Turkey Medical Cannabis Market

• End users in Turkey’s emerging medical cannabis market, ranging from healthcare providers to government-regulated pharmacies, are beginning to share valuable insights on product performance and accessibility. Physicians involved in pain management and neurology report that cannabis-based oils and extracts offer precise dosing and faster therapeutic effects compared to traditional treatments, making them a welcome addition to patient care. For instance, doctors treating patients with chronic pain highlight improved patient compliance when using standardized cannabis formulations, noting reduced side effects and better long-term management. At the same time, licensed pharmacists appreciate the potential to diversify treatment options, though they stress the importance of consistent product quality and reliable supply to maintain trust with both patients and the healthcare system.
• Despite these encouraging experiences, recurring concerns reveal important unmet needs. Patients and physicians alike cite affordability and limited availability as barriers to wider adoption, particularly in rural areas where access to licensed pharmacies is restricted. There is also feedback on the lack of customized product formats for different patient groups, such as elderly patients requiring easy-to-administer options or pediatric cases needing controlled microdosing. Stakeholders emphasize that addressing these gaps through targeted R&D, improved distribution frameworks, and clearer regulatory guidance could not only strengthen patient outcomes but also open growth opportunities for domestic producers and international collaborators. By closing these gaps, manufacturers and policymakers can foster innovation, build stronger confidence among end users, and position Turkey as a competitive player in the global medical cannabis landscape.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In August 2025, Türkiye passed a landmark health law legalizing the controlled sale of medical cannabis in pharmacies to improve patient access to pain relief and reduce import dependence, while boosting the country’s competitiveness in the global market. The Agriculture and Forestry Ministry will oversee hemp cultivation, the Health Ministry will handle processing, licensing, exports, and sales, and the Interior Ministry will monitor compliance, with all products tracked through a national electronic pharmaceutical system.
• In August 2025, Curaleaf Holdings Inc., a leading global provider of cannabis consumer products, reported USD 315 million in Q2 revenue with USD 41 million coming from international markets and announced it has been awarded a license to operate in Turkey, expanding its presence to 15 countries alongside 17 U.S. states. The company achieved a 49% adjusted gross margin and USD 66 million in adjusted EBITDA, while CEO Boris Jordan highlighted Curaleaf’s focus on product quality, customer service, and supply chain excellence to drive future growth in the rapidly expanding global cannabis market.
• In October 2024, the Government of Türkiye, through a presidential decree published in the Official Gazette, set an annual hemp cultivation quota of 5,000 square meters and 120,000 plants exclusively for producing pharmaceutical active ingredients. The Ministry of Agriculture and Forestry, the state authority overseeing cultivation, will manage quota allocation, while universities and research institutes with permits are exempt for RandD projects. The move reflects Türkiye’s effort to balance economic opportunity and medical potential, as industrial hemp is increasingly seen as a strategic crop for sectors like pharmaceuticals, textiles, and automotive, reducing reliance on imported raw materials.

Top Strategies Followed by Global Turkey Medical Cannabis Market Players

• Established market leaders typically invest heavily in research and development to drive innovation and create high-performance products that meet stringent quality and efficacy standards. These players prioritize the development of advanced formulations and delivery methods, leveraging scientific breakthroughs to differentiate their offerings in an increasingly saturated environment. Additionally, these companies often forge strategic partnerships and alliances with major industry players, including Original Equipment Manufacturers (OEMs), distributors, and pharmaceutical firms, to enhance their supply chain efficiency and solidify their position in the market.
  • In January 2025, SOMAÍ Pharmaceuticals partnered with Thailand’s Pacific Cannovation Company Limited (PACCAN) to expand global access to high-quality medical cannabis, combining SOMAÍ’s EU-GMP regulatory network with PACCAN’s ethical cultivation expertise. This collaboration also signals opportunities for emerging markets like Turkey, where new hemp quotas for pharmaceutical use are shaping the country’s medical cannabis landscape.

• Mid-level competitors in the Turkey medical cannabis market carve out a competitive edge by focusing on cost-effective solutions that strike a balance between quality and affordability. These players primarily target price-sensitive consumers, including patients and healthcare providers looking for budget-friendly alternatives without compromising product reliability. To strengthen their market position, mid-level companies often engage in collaborative ventures to augment production capacity, acquire new technology, and expand their market presence.
  • For example, Pharmananda Pharmaceuticals positions itself by providing medical cannabis formulations at competitive pricing for the Turkish healthcare sector. It collaborates with agricultural partners for hemp/cannabis sourcing and maintains partnerships with local distributors, ensuring affordability and accessibility.

• Small-scale players in the Turkish medical cannabis industry distinguish themselves by specializing in niche markets and innovative product features that meet specific patient needs or regulatory requirements. These companies frequently adopt cutting-edge cultivation and extraction technologies to improve product quality and maintain competitiveness against larger rivals. Small players also leverage regional advantages by building local alliances with startups, local manufacturers, or research institutions, facilitating easier market entry and boosting visibility within particular geographic or demographic segments.
  • For example, Kenevirco is a Turkish hemp and cannabis startup specializing in industrial hemp cultivation and medical cannabis pilot projects. By leveraging advanced cultivation methods and local alliances with research institutions, Kenevirco focuses on innovation in niche areas such as Cannabidiol (CBD) extracts and functional health supplements. Its regional partnerships and adaptability allow it to quickly respond to regulatory changes while maintaining visibility in the local ecosystem.

Market Report Scope

Turkey Medical Cannabis Market Report Coverage

Turkey Medical Cannabis Market Dynamics

To learn more about this report, Download Free Sample

Turkey Medical Cannabis Market Driver - Increasing Legalization and Regulation of Medical Cannabis

The growing acceptance and implementation of legalized frameworks surrounding medical cannabis in Turkey is significantly driving the expansion of the country’s medical cannabis market. In recent years, Turkish authorities have moved toward establishing clear and comprehensive regulations that facilitate the cultivation, production, and distribution of medical cannabis products strictly for therapeutic purposes. This regulatory clarity not only reduces the ambiguities and risks previously associated with the market but also encourages investments and research initiatives focused on cannabis-based treatments. Furthermore, government-backed pilot programs and licensing schemes have created a controlled environment that ensures product quality and patient safety, fostering greater trust among healthcare providers and patients. The alignment of regulatory policies with international medical cannabis standards is also paving the way for Turkey to tap into the global medical cannabis ecosystem.

For instance, in July 2025, the Turkish Parliament approved new healthcare legislation permitting the controlled sale of medicinal cannabis in pharmacies, limited to products with less than 0.3% THC. Overseen by the Ministry of Agriculture and Forestry for cultivation and by the Ministry of Health for processing, licensing, and pharmacy distribution, all products will be tracked through an electronic monitoring system to ensure compliance. Licensed pharmacies will exclusively handle sales for prescribed treatments, with industry experts like Taner Ercanli of the Turkish Pharmacists Association stressing that these pharmaceutical-grade cannabis products offer analgesic and antidepressant benefits and remain entirely distinct from recreational use.

Turkey Medical Cannabis Market Opportunity - Growing Investment in Cannabis Cultivation and Processing Facilities

The Turkey medical cannabis market is witnessing a significant opportunity driven by increasing investments in cannabis cultivation and processing infrastructure. As regulatory frameworks evolve to accommodate the medical use of cannabis, both domestic and international investors are showing heightened interest in establishing large-scale cultivation farms and state-of-the-art processing facilities within Turkey. This influx of capital is aimed at leveraging Turkey’s favorable climatic conditions and strategic geographic location to position the country as a regional hub for medical cannabis production and export.

Advanced cultivation technologies, including controlled environment agriculture and automated harvesting systems, are being introduced, which enhance yield quality and consistency—critical factors for satisfying stringent pharmaceutical standards. Additionally, investments are channeling toward processing capabilities, focusing on extraction, refinement, and formulation of cannabis-based products such as oils, tinctures, and capsules to meet the rising the demand from healthcare providers and patients.

Analyst Opinion (Expert Opinion)

• The Turkey medical cannabis market is slowly gaining momentum as regulatory support becomes clearer, with the government opening limited but structured avenues for research and pharmaceutical use. Growing awareness of the therapeutic potential of cannabis-based medicines for conditions such as chronic pain, epilepsy, and cancer-related symptoms is creating steady demand. Advances in cultivation technologies and controlled production facilities are helping local stakeholders build capacity, while interest from international players signals that the market could benefit from partnerships and knowledge transfer. Still, challenges remain in the form of stringent regulations, limited patient access, and the need for clear frameworks to balance safety, supply, and commercial opportunity. At the same time, opportunities are emerging in areas like pharmaceutical innovation, clinical trials, and government-backed pilot projects aimed at positioning Turkey as a regional hub for regulated cannabis-based medicine.
• Globally, several high-profile events such as the International Cannabis Business Conference (ICBC) in Berlin and Zurich, the Cannabis Europa Conference in London, and MedCann World Forum in Malta have provided platforms over the past two to three years where policy makers, regulators, and industry leaders have shared experiences and debated pathways for medical cannabis adoption. Such forums have shaped investor confidence and policy discussions that indirectly influence emerging markets like Turkey. Real-world examples underscore this trajectory: Curaleaf’s expansion into new international markets, European pilot projects to integrate cannabis into mainstream healthcare, and regional collaborations across the Middle East on controlled cannabis research programs demonstrate the growing seriousness of this industry. These instances suggest that Turkey, while still cautious, is part of a broader global wave where structured regulation, cross-border cooperation, and medical validation are expected to guide the market’s next phase of growth.

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Oils and Extracts
  • Dried Flower
  • Capsules and Tablets
  • Topicals and Creams
• Derivative Insights (Revenue, USD Mn, 2020 - 2032)
  • Cannabidiol (CBD)
  • Tetrahydrocannabinol (THC)
  • Balanced CBD–THC
  • Other Cannabinoids
• Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Pain Management
  • Neurological Disorders (Epilepsy, Multiple Sclerosis, Parkinson’s, etc.)
  • Mental Health Disorders (Anxiety, Depression, PTSD)
  • Cancer Treatment Support (Nausea, Appetite Stimulation)
  • Chronic Diseases (Arthritis, Diabetes complications, etc.)
  • Other Therapeutic Uses
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Patients (Individual Consumers)
  • Research and Academic Institutions
  • Healthcare Providers / Clinics
  • Pharmaceutical Companies
• Key Players Insights
  • Kenevirco
  • Pharmananda Pharmaceuticals
  • Aurora Cannabis Inc.
  • Organigram Holdings Inc.
  • Cronos Group Inc.
  • Curaleaf Holdings Inc.
  • Other Prominent Players

Sources

Primary Research Interviews

• Industry Stakeholders List
  • Turkish Pharmacists Association (TEB)
  • Turkish Hemp Industrialists Association
• End Users List
  • Licensed Hospital Procurement Managers in Turkey
  • Chronic Pain & Neurology Specialists in Turkish Clinics

Government and International Databases

• Turkish Statistical Institute (TurkStat)
• Republic of Turkey Ministry of Health
• Republic of Turkey Ministry of Agriculture and Forestry
• World Health Organization (WHO)
• United Nations Office on Drugs and Crime (UNODC)
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Trade Publications

• Hemp Today
• Cannabis Business Times
• MJBizDaily (International Section)
• Hemp Industry Daily
• European Pharmaceutical Review
• Pharmaceutical Technology

Academic Journals

• Journal of Cannabis Research
• International Journal of Drug Policy
• Journal of Ethnopharmacology
• Turkish Journal of Medical Sciences
• European Journal of Pharmacology
• Frontiers in Pharmacology

Reputable Newspapers

• Hurriyet Daily News
• Anadolu Agency
• Daily Sabah
• BBC News (Europe Section)
• The Guardian (Global Health Section)
• Reuters Health

Industry Associations

• Turkish Pharmacists Association (TEB)
• International Cannabis and Cannabinoids Institute (ICCI)
• European Industrial Hemp Association (EIHA)
• International Association for Cannabinoid Medicines (IACM)
• Turkish Medical Association (TTB)
• Federation of Pharmaceutical Manufacturers’ Associations of Turkey (IEIS)

Public Domain Resources

• World Bank Open Data
• FAOSTAT (Food and Agriculture Organization)
• United Nations Comtrade Database
• OECD Health Statistics
• European Commission Public Health Portal

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years